DOCSLIB.ORG

Bristol Myers Squibb

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Bristol Myers Squibb ASSOCIATION OF COMMUNITY CANCER CENTERS This content is provided for informational purposes only and is not meant to substitute for medical advice, diagnosis, or treatment purposes. ACCC does not endorse or recommend any specific prescription drug or any other information in this publication. The programs represented herein have been set up primarily by drug companies that offer free or low-cost drugs to insured, uninsured, or underinsured individuals who cannot afford their medication. Companies offer these programs voluntarily, and the government does not require the provision of free medicine. All content and links reflect accuracy on this date. The ACCC Patient Assistance & Reimbursement Guide was updated starting March 1, 2021 and published online in April 2021. This publication is updated four times a year. Visit accc-cancer.org/PatientAssistanceGuide to download and print the most up-to-date information on cancer drug assistance and reimbursement programs. 2021 PATIENT ASSISTANCE & REIMBURSEMENT GUIDE 1 A Message from Jorge J. Garcia PharmD, MS, MHA, MBA, FACHE, ACCC Board of Trustees Member and OPEN Advisory Committee Member This year ACCC is proud to publish the 10th print edition of its Patient Assistance & Reimbursement Guide. ACCC Immediate-Past President Ali McBride, PharmD, MS, BCOP, shared with us last year how cancer pro- grams and practices across the nation have expanded their financial advocacy efforts to include pharmacy and other supportive care staff as part of this critical patient service. Recognizing that our financial naviga- tion and pharmacy members are both “super-users” of this guide and the front-line staff responsible for helping patients with cancer overcome financial toxicity, ACCC made a thoughtful decision to more closely align its Patient Assistance & Reimbursement Guide with the ACCC Financial Advocacy Network (FAN) and the ACCC Oncology Pharmacy Education Network (OPEN). Leveraging color and branding—note the purple and orange hues long associated with the ACCC financial advocacy and pharmacy initiatives—and content, this year’s guide highlights the power of multidisciplinary care and the passion that cancer care teams have for treating our patients’ mind, body, and spirit. As we head into a new year, we must also learn from our experiences in 2020 with the COVID-19 public health emergency. The impact of this pandemic is felt across all walks of life, especially among our frontline workers and our patients with cancer. Not only are our patients considered an at-risk population for getting COVID-19, but the country’s economic downturn as a result of the worldwide pandemic has taken a serious toll on these patients—regardless of their insurance coverage status. Many of our patients have lost their jobs and/or healthcare coverage, and they need financial assistance now more than ever. I want to take this time to thank all the financial navigators, financial counselors, pharmacy staff, social workers, and anyone else who has helped their patients receive the financial assistance they need. For those new to financial advocacy, ACCC has updated its patient assistance flowchart (page 14) and developed a practical, step-by-step instruction to guide you as you help your patients access and pay for their cancer therapies. The article (pages 7-13) features members features members of the ACCC Financial Advocacy Network, who shared with us their experiences and workflows to help guide those new to finan- cial navigation. I am also excited to share that ACCC has been hard at work looking to the future of this resource and how to best meet the changing needs of its members. Specifically, ACCC is exploring ways to create a robust and user-friendly digital Patient Assistance & Reimbursement Guide as a companion piece to the annual print edition—more news to come on this in 2021. As the pace of drug approvals and the addition of novel agents increase exponentially, continual education and learning are needed. To help in this effort, the Patient Assistance & Reimbursement Guide is updated on a quarterly basis with the most updated information on cancer drug assistance and reimbursement programs, including directions on how to apply and links to enrollment forms. But we want your help! As you use this guide throughout the year, if you know of any changes, updates, and/or corrections to the information within, let us know. Please direct all comments, questions, comments, and feedback to Maddelynne Parker at [email protected]. 2021 PATIENT ASSISTANCE & REIMBURSEMENT GUIDE 1 ASSOCIATION OF COMMUNITY CANCER CENTERS 1 A Message from Dr. Jorge J. Garcia, ACCC Board of Trustees Member and OPEN Advisory Committee Member 9 Fighting Financial Toxicity: How Financial Navigators Help Patients with All Insurance Types By Teri Brown; Aimee Hoch, LSW; Jordan Karwedsky; Jennifer Paquet, RN, BSN; and Jeanie Troy 16 Financial Navigation Flowchart Pharmaceutical Company Patient Sanofi Genzyme 85 Assistance & Reimbursement Programs Seagen 87 AbbVie, Inc. 17 Sun Pharmaceutical Industries, Inc. 88 Amgen, Inc. 18 Taiho Oncology 90 Astellas Pharma U.S., Inc. 20 Takeda Oncology 92 AstraZeneca 23 TerSera Therapeutics 94 Bayer HealthCare Pharmaceuticals, Inc. 25 Teva Oncology 95 BeiGene 29 Blueprint Medicines 30 Medical Device & Testing Patient Bristol Myers Squibb 32 Assistance & Reimbursement Programs Celgene Oncology 34 Adaptive Biotechnologies 98 Coherus BioSciences 36 Foundation Medicine 100 Daiichi Sankyo 37 Other Patient Assistance Programs & Resources Daiichi Sankyo and AstraZeneca 39 Agingcare.com® 104 Eisai Co., Ltd. 41 AuntBertha.com 104 Eli Lilly and Company 43 BenefitsCheckUp® 104 EMD Serono, Inc. 46 Epizyme, Inc. 48 CancerCare® 104 Exelixis, Inc. 50 Cancer Financial Assistance Coalition 105 Genentech, Inc. 51 Co-Pay Relief 105 GlaxoSmithKline 53 FamilyWize® 106 G1 Therapeutics 55 Good Days® 106 Immunomedics 56 HealthWell Foundation® 107 Incyte Corporation 57 The Leukemia & Lymphoma Society 107 Ipsen Biopharmaceuticals, Inc. 59 Medicine Assistance Tool 108 Janssen Biotech, Inc. 61 NeedyMeds 108 Jazz Pharmaceuticals 63 Patient Access Network Foundation 109 Karyopharm Therapeutics 64 Patient Advocate Foundation 109 Kite Pharma 66 RxAssist 110 Merck 67 MorphoSys 69 RxHope™ 108 Mylan 71 Rx Outreach® 110 Novartis Pharmaceuticals Corporation 73 Quick Reference Guide 114 Oncopeptides 75 Pfizer, Inc. 77 Pharmacyclics, LLC 79 The ACCC Patient Assistance & Reimbursement Guide was printed in January 2021. This publication is updated four times a year. Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme 81 Visit accc-cancer.org/PatientAssistanceGuide to download and Sandoz 83 print the most up-to-date information on cancer drug assistance and reimbursement programs. 2 ASSOCIATION OF COMMUNITY CANCER CENTERS 2021 PATIENT ASSISTANCE & REIMBURSEMENT GUIDE 3 Patient Assistance & Reimbursement Erivedge® (vismodegib) capsules 51 Assistance Programs Erwineaze® (asparaginase Erwinia chrysanthemi) for injection 63 Exjade® (deferasirox) tablets for oral suspension 73 by drug or product Faslodex® (fulvestrant) injection 23 Abraxane® (paclitaxel protein-bound particles Femara® (letrozole) tablets 73 for injectable suspension) (albumin-bound) 34 Fulphila® (pegfilgrastim-jmdb) injection 71 Adakveo® (crizanlizumab-tmca) for IV infusion 73 Gardasil®9 (Human Papillomavirus 9-valent Adcetris® (brentuximab vedotin) for injection 87 Vaccine, Recombinant) 67 Afinitor® (everolimus) tablets 73 Gavreto™ (pralsetinib) capsules 30 Alecensa® (alectinib) capsules 51 Gazyva® (obinutuzumab) injection 51 Alimta® (pemetrexed) for injection 43 Gleevec® (imatinib mesylate) tablets 73 Aliqopa™ (copanlisib) for injection 25 Granix® (tbo-filgrastim) injection 95 Alunbrig® (brigatinib) tablets 92 Halaven® (eribulin mesylate) injection 41 Aranesp® (darbepoetin alfa) injection 18 Herceptin® (trastuzumab) injection for intravenous use 51 Aromasin® (exemestane) tablets 77 Herceptin Hylecta™ (hyaluronidase-oysk) injection 51 Avastin® (bevacizumab) injection for IV use 51 Herzuma® (trastuzumab-pkrb) for injection 95 Ayvakit™ (avapritinib) tablets 30 Ibrance® (palbociclib) capsules 77 Balversa™ (erdafitinib) tablets 61 Iclusig® (ponatinib) tablets 92 Bavencio® (avelumab) injection 46 Idamycin® (idarubicin hydrochloride) injections 77 Bendeka® (bendamustine HCI) injection 95 Idhifa® (enasidenib) tablets 34 Besponsa® (inotuzumab ozogamicin) injection for IV infusion 77 Imbruvica® (ibrutinib) capsules 79 Blenrep (belantamab mafodotin-blmf) for injection 53 Imfinzi® (durvalumab) injection for intravenous use 23 Blincyto® (blinatumomab) for injection 18 Imlygic® (talimogene laherparepvec) suspension Bosulif® (bosutinib) tablets 77 for injection 18 Braftovi® (encorafenib) capsules 77 Inlyta® (axitinib) tablets 77 ™ Brukinsa (zanubrutinib) capsules 29 Inqovi®(decitabine and cedazuridine) tablets 90 Cabometyx® (cabozantinib) tablets 50 Inrebic® (fedratinib) capsules 34 Calquence® (acalabrutinib) capsules 23 Intron® A (interferon alfa-2b, recombinant) Camptosar® (irinotecan hydrochloride) injection 77 for injection 67 Cometriq® (cabozantinib) capsules 50 Iressa® (gefitinib) 23 Cosela™ (trilaciclib) for injection 55 Istodax® (romidepsin) for injection 34 Cotellic® (cobimetinib) tablets 51 Jadenu® (deferasirox) tablets 73 Cyramza® (ramucirumab) injection 43 Jakafi® (ruxolitinib) tablets 57 Darzalex® (daratumumab) injection for intravenous infusion 61 Jevtana® (cabazitaxel) injection 85 Darzalex Faspro™ (daratumumab and hyaluronidase-fihj) Kadcyla® (ado-trastuzumab emtansine)
Load more

Recommended publications
  • Medical Loss Ratio Regulation in the Pharmaceutical Industry
    BYU Law Review Volume 2018 Issue 1 Article 8 Fall 8-31-2018 Leveraging Pharma to Lower Premiums: Medical Loss Ratio Regulation in the Pharmaceutical Industry Cami R. Schiel Follow this and additional works at: https://digitalcommons.law.byu.edu/lawreview Part of the Law Commons, and the Pharmaceutical Preparations Commons Recommended Citation Cami R. Schiel, Leveraging Pharma to Lower Premiums: Medical Loss Ratio Regulation in the Pharmaceutical Industry, 2018 BYU L. Rev. 205 (2018). Available at: https://digitalcommons.law.byu.edu/lawreview/vol2018/iss1/8 This Comment is brought to you for free and open access by the Brigham Young University Law Review at BYU Law Digital Commons. It has been accepted for inclusion in BYU Law Review by an authorized editor of BYU Law Digital Commons. For more information, please contact [email protected]. 5.SCHIEL_FIN_NOHEADER.DOCX (DO NOT DELETE) 8/17/18 10:42 AM Leveraging Pharma to Lower Premiums: Medical Loss Ratio Regulation in the Pharmaceutical Industry Many recognize escalating drug prices as a significant dilemma related to America’s rising healthcare costs. Yet few can agree on what to do about them. Unaffordable drug prices are a result of many complex forces. One theory to address this problem is to reduce all government intervention and let normal market forces act as they usually do to bring the goods’ prices down to consumer-friendly ranges. However, the pre- scription drug market is not, and perhaps never can be, a normal market. Reasons for this include (1) a lack of price transparency, (2) information and control asymmetries between patients and physicians, (3) third-party payors, (4) demand that remains constant irrespective of any exorbitant price increases (i.e., market inelasticity), and (5) patent-ensured mono- polies.
    [Show full text]
  • Price Gouging the American Public
    The Pharma Big 10: Price Gougers, Tax Dodgers DecemberNovemb e2017r 2017 THE PHARMA BIG 10: PRICE GOUGERS, TAX DODGERS CREDITS Authors William Rice, senior writer, Kayla Kitson, senior researcher, and Frank Clemente, executive director, Americans for Tax Fairness Research Americans for Tax Fairness: William Rice and Kayla Kitson. Institute on Taxation and Economic Policy for corporate financial and tax data: Richard Phillips, senior policy analyst, and Matthew Gardner, senior fellow. Special thanks to Open Society Foundations for a generous grant in support of this work and to Azzi Momenghalibaf, senior program officer with the Open Society Public Health Program. Special thanks to Leigh Purvis at AARP Public Policy Institute for providing prescription-drug retail price data. Report design by Katie Vann Americans for Tax Fairness is a diverse coalition of 425 national and state endorsing organizations that collectively represent tens of millions of members. The organization was formed on the belief that the country needs comprehensive, progressive tax reform that results in greater revenue to meet our growing needs. ATF is playing a central role in Washington and in the states on federal tax-reform issues. Americans for Tax Fairness 1101 17th Street NW, Suite 301 Washington, D.C. 20036 www.AmericansForTaxFairness.org Table of Contents Introduction & Key Findings ...................................................................................................... 4 Pharma Big 10 Price Gouging ............................................................................................... 6 Figure 1: Increase in Select Prescription Drug Prices for Medicare, Medicaid & Retail Customers, 2011—2015 .. 7 Table 1: Price Increases on Selected U.S. Prescription Drugs Purchased Through Medicare, 2011-2015 ............ 8 Table 2: Price Increases on Selected U.S. Prescription Drugs Purchased Through Medicaid, 2011-2015 ...........
    [Show full text]
  • Medical Loss Ratio Regulation in the Pharmaceutical Industry Cami R
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Brigham Young University Law School BYU Law Review Volume 2018 | Issue 1 Article 8 Fall 8-31-2018 Leveraging Pharma to Lower Premiums: Medical Loss Ratio Regulation in the Pharmaceutical Industry Cami R. Schiel Follow this and additional works at: https://digitalcommons.law.byu.edu/lawreview Part of the Law Commons, and the Pharmaceutical Preparations Commons Recommended Citation Cami R. Schiel, Leveraging Pharma to Lower Premiums: Medical Loss Ratio Regulation in the Pharmaceutical Industry, 2018 BYU L. Rev. 205 (2018). Available at: https://digitalcommons.law.byu.edu/lawreview/vol2018/iss1/8 This Comment is brought to you for free and open access by the Brigham Young University Law Review at BYU Law Digital Commons. It has been accepted for inclusion in BYU Law Review by an authorized editor of BYU Law Digital Commons. For more information, please contact [email protected]. 5.SCHIEL_FIN_NOHEADER.DOCX (DO NOT DELETE) 8/17/18 10:42 AM Leveraging Pharma to Lower Premiums: Medical Loss Ratio Regulation in the Pharmaceutical Industry Many recognize escalating drug prices as a significant dilemma related to America’s rising healthcare costs. Yet few can agree on what to do about them. Unaffordable drug prices are a result of many complex forces. One theory to address this problem is to reduce all government intervention and let normal market forces act as they usually do to bring the goods’ prices down to consumer-friendly ranges. However, the pre- scription drug market is not, and perhaps never can be, a normal market.
    [Show full text]
  • PRESCRIPTION DRUG COUPON STUDY Report to the Massachusetts Legislature JULY 2020
    COMMONWEALTH OF MASSACHUSETTS HEALTH POLICY COMMISSION PRESCRIPTION DRUG COUPON STUDY Report to the Massachusetts Legislature JULY 2020 EXECUTIVE SUMMARY In this report, required by Chapter 363 of the 2018 Session Prescription drug coupons are currently allowed in all 50 Laws, the Massachusetts Health Policy Commission (HPC) states for commercially-insured patients. Federal health examines the use and impact of prescription drug coupons insurance programs, such as Medicare, Medicaid, Tricare in Massachusetts. This report focuses on coupons issued by and Veteran’s Administration, prohibit the use of coupons pharmaceutical manufacturers that reduce a commercial based on federal anti-kickback statutes. Massachusetts patient’s cost-sharing. Prescription drug coupons are offered became the last state to authorize commercial coupon use almost exclusively on branded drugs, which comprise only in 2012 but continues to prohibit manufacturers from 10% of all prescriptions dispensed in the U.S., but account offering coupons and discounts on any prescription drug for 79% of total drug spending. Despite the immediate ben- that has an “AB rated” generic equivalent as determined efit of drug coupons to patients, policymakers and experts by the Food and Drug Administration (FDA). The 2012 debate whether and how coupons should be allowed in the law authorizing coupons in Massachusetts also contained commercial market given the potential relationship between a sunset provision, under which the law would have been coupon usage and increased spending on branded drugs repealed on July 1, 2015. However, this date of repeal versus lower cost alternatives. was postponed several times and ultimately extended to January 1, 2021. Massachusetts has long sought to con- Coupons reduce or eliminate the patient’s cost-sharing sider the impact of drug coupons on the Commonwealth’s responsibility required by the patient’s insurance plan, while landmark cost containment goals, as well as the benefits for the plan’s costs for the drug remain unchanged.
    [Show full text]
  • Physicians' Attitudes About Prescribing and Knowledge of The
    ORIGINAL INVESTIGATION Physicians’ Attitudes About Prescribing and Knowledge of the Costs of Common Medications Steven Reichert, MD; Todd Simon, MD; Ethan A. Halm, MD, MPH Background: Compliance with medical therapy is of- only 13% had been formally educated about drug costs. ten compromised because patients cannot afford to pay Regarding insurance coverage, 94% of physicians gave for medications. Inadequate physician knowledge of drug strong consideration to the cost of medications when pa- costs may unwittingly contribute to this problem. tients were self-paying, 68% when patients had Medi- care, and 30% when patients had Medicaid or were par- Objective: To measure attitudes about prescribing and ticipants in a health maintenance organization with a knowledge of medication costs and compare differences prescription plan. Physicians’ estimates of the cost of a among attending physicians and residents. month’s supply of 33 commonly used medications were accurate in 45% of cases, too low for 40%, and too high Design/Participants: Written survey of internal medi- for 15%. The costs of brand-name and expensive drugs cine house staff and general medicine attending physi- were most likely to be underestimated. House officers were cians in an urban hospital-based primary care center. less cost-conscious than attending physicians. Results: One hundred thirty-four of 189 physicians re- Conclusions: Physicians were predisposed to being sponded (71% response rate). Seventy percent of respon- cost-conscious in their prescribing habits, but lacked dents were house officers and 30% were attending phy- accurate knowledge about actual costs and insurance sicians. Eighty-eight percent of physicians felt the cost coverage of drugs.
    [Show full text]
  • Prices of Diabetes Drugs for Seniors and the Uninsured in the United States and Abroad
    Prices of Diabetes Drugs for Seniors and the Uninsured in the United States and Abroad California’s 44th Congressional District Staff Report Committee on Oversight and Reform U.S. House of Representatives April 2019 oversight.house.gov EXECUTIVE SUMMARY More than 30 million people in the United States, including more than one in four seniors, have diabetes. Patients with diabetes rely on prescription drugs, including insulin, to help manage their conditions. Over the past two decades, manufacturers have systematically and dramatically raised the prices of their insulin products by more than tenfold—often in lockstep. These high prices lead many people to ration or stop taking their medications, which can result in serious health complications and even death, as the Committee heard in direct testimony earlier this year. The prices of diabetes medications—and insulin in particular—are far higher in the United States than they are overseas, in part because certain federal programs lack the authority to negotiate directly with drug manufacturers. In order to assess the impact of the high prices of diabetes medications on seniors and uninsured patients, this report was prepared by the staff of the House Committee on Oversight and Reform for the 44th Congressional District of California. Costs to Seniors and Medicare This report estimates that there are approximately 17,000 Medicare beneficiaries in the district who have been diagnosed with diabetes. The 50 most popular brand-name diabetes medications used by these beneficiaries are available at significantly lower prices in other countries. For example, the cost of these drugs to the Medicare program in the district are 4.3 times the cost in Australia, 3.3 times the cost in the United Kingdom, and 2.5 times the cost in Canada.
    [Show full text]
  • Patient Cost-Saving Guide at Caremount Medical, Our Primary Focus Is Delivering High-Quality Care That Improves Our Patient’S Experience and Health
    MEDICATION RESOURCES Patient Cost-Saving Guide At CareMount Medical, our primary focus is delivering high-quality care that improves our patient’s experience and health. Since exceptional care is our objective, we understand prescribed treatments may not always be covered by your specific insurance plan. CONTACT US We do our best to provide alternatives when applicable and available. We WEB: caremountmedical.com encourage you to work with your insurance company to verify coverage If you would like to speak to someone in order to avoid any unexpected costs. Most plans provide a PHONE: formulary about your care, please contact our Care (preferred drug list), and can advise of lower cost alternatives if the specific Coordination Team: (845) 202-6340 drug you are prescribed is not covered. Always speak with your doctor first to confirm if the alternative may be appropriate for your care and CAREMOUNT PATIENT ASSISTANCE TEAM: condition. (914) 440-2840 With prescription drugs costs continuing to rise, we wanted to provide you MEDICARE PATIENTS: Contact Medicare with a resource to take advantage of certain cost saving programs that are at 1-800-633-4273 available to help offset any medication costs. Please see the list below for a Or reach out to your Part D prescription drug quick reference guide to possible cost saving resources. plan to verify any specific benefits and coverage. Resource Contact About Some pharmaceutical companies offer assistance programs for the drugs they AstraZeneca, Merck, manufacture. See their website to review Drug manufacturer assistance programs Novartis, Pfizer, etc. any eligibility criteria. Medicare and Social Security offer a program Extra Help (800) 772-1213 to reduce Part D plan premiums and copays for those for qualify.
    [Show full text]
  • Affordability Options for Prescription Drugs
    Affordability Options for Prescription Drugs In recent years healthcare choices have expanded significantly, many due to advances in pharmaceutical treatments. Although prescription drug expense represents only a small portion of total U.S. healthcare spending1, the out-of-pocket costs for individual patients can be significant. This tool highlights some of the resources that are available to assist patients with their prescription drug costs and correlates the options with primary insurance status. This resource is presented for informational purposes only and is not intended to provide reimbursement or legal advice. Laws, regulations, and policies concerning reimbursement are complex and are updated frequently. While we have made an effort to be current as of the publication date, the information may not be as current or comprehensive when you view it. In addition, this information does not represent any statement, promise or guarantee by Johnson & Johnson Health Care Systems Inc. about coverage, levels of reimbursement or payment. Please consult with your payer organization(s) for local or actual coverage and reimbursement policies and determination processes. Please consult with your counsel or reimbursement specialist for any reimbursement or billing questions specific to your institution. 1. Prescription drugs represented 10% of total health care spending in 2010; Source: National Center for Health Statistics. (2013). Health, United States, 2012; Table 113. Available at: http://www.cdc.gov/nchs/data/hus/hus12.pdf#113. 1 Options Options
    [Show full text]
  • Excessive Pricing of Off-Patent Pharmaceuticals: Hatch It Or Ratchet?
    39546-nyu_92-4 Sheet No. 194 Side B 10/12/2017 08:00:42 \\jciprod01\productn\N\NYU\92-4\NYU412.txt unknown Seq: 1 11-OCT-17 15:35 EXCESSIVE PRICING OF OFF-PATENT PHARMACEUTICALS: HATCH IT OR RATCHET? JENNIFER L. GRABER* There is growing concern over the pharmaceutical industry’s ability to set and raise drug prices as it sees fit. The price of a drug that has not been protected by a patent for decades can suddenly increase—or “ratchet”—as much as 10,000%. This Note identifies the problem of ratcheting drug prices and considers whether these abrupt changes in drug prices derive from a longstanding problem inherent in the United States’ pharmaceutical regulatory regime. It then considers the most commonly sug- gested mechanism for countering high drug prices—stimulating competition in the pharmaceutical market—but ultimately concludes that focusing solely on increasing competition constructs an overly simplistic view of ratcheting drug prices. In order to find an effective solution to unexpected increases in drug prices, this Note evaluates a small subset of pharmaceuticals that have recently undergone a sudden price increase and separates the ratcheting events into two categories: (1) those that occur as a result of natural deviations in the market, and (2) those that occur due to business tactics that take advantage of vulnerabilities in the drug market. It concludes that under this categorization, antitrust law may provide an effective solution specifically directed at ratcheting events of the second category— those driven by anticompetitive behavior. INTRODUCTION ................................................. 1147 R I. THE RISE OF DRUG PRICES AND THE LAWS THAT REGULATE PRICING....................................
    [Show full text]
  • State Efforts to Lower Consumer Cost-Sharing for High-Cost Prescription Drugs Stakeholder Perspectives
    HEALTH POLICY CENTER State Efforts to Lower Consumer Cost-Sharing for High-Cost Prescription Drugs Stakeholder Perspectives Sandy Ahn and Sabrina Corlette GEORGETOWN UNIVERSITY HEALTH POLICY INSTITUTE August 2017 Federal action to lower the cost of prescription drugs has broad support across the political spectrum. In one recent poll, over 60 percent of Americans identified lowering the cost of prescription drugs as a “top priority” for the Trump administration and Congress (Kirzinger et al. 2017). But to date, there has been little change in federal policy on drug pricing and costs. Perhaps in response to federal inaction on this issue, state legislators have introduced 80 bills in 2017 alone that attempt to lower prescription drug costs. One area of focus for states has been high out-of-pocket drug costs for consumers with chronic conditions such as multiple sclerosis or cancer that require treatment with specialty drugs. California, Colorado, Delaware, Louisiana, Maryland, Montana, New York, and Vermont have leveraged their authority to regulate health insurance to lower cost-sharing charges for consumers using these specialty drugs. To assess the goals and impact of these state policies, we conducted interviews with regulators, insurers, and consumer advocacy groups in four of the eight states: California, Colorado, Louisiana, and Montana. Most of the stakeholders said that these state policies have had their intended impact by reducing consumers’ out-of-pocket costs for expensive prescription drugs and by preventing insurers from discriminating against high-cost enrollees through the design of plan formularies. However, stakeholders had mixed opinions about the policies. Insurer respondents noted that they shift costs to other consumers, either through higher premiums or cost-sharing for other services, and mask the larger problem of escalating drug prices.
    [Show full text]
  • Nine Ways to Deal with Escalating Drug Costs
    Nine Ways to Deal with Escalating Drug Costs By Keith Loria Nov 7, 2018 As drug costs continue to increase at an unsustainable rate, many industry insiders believe the current trajectory of pharmaceutical expenses will eventually bankrupt the U.S. healthcare system. Girish Dighe, PharmD, MS, director of pharmacy, business services, at OhioHealth, a not-for- profit system of hospitals and healthcare providers in Columbus, notes that there are fundamental flaws within the healthcare system causing vastly complex challenges to drug pricing. “The multitude of stakeholders involved in the drug channels for bringing patients access to medications (manufacturers, insurers, pharmacy benefit managers (PBMs), providers, retail pharmacies, wholesalers) revolves around financial incentives driving each stakeholder,” Dighe says. “The growing spread between pharmaceutical list price and net price negotiated by drug channel stakeholders has negatively impacted patients’ out-of- pocket costs.” According to a recent survey from NORC at the University of Chicago and the West Health Institute, 77% of Americans believe prescription drug prices are unreasonably high. President Donald Trump took a big stance against rising drug prices early in his tenure and since then some drug companies—Pfizer, Novartis, Sanofi, Roche, and Merck among them—have announced that they’re freezing or even lowering drug costs. Alex Azar, HHS secretary, recently announced that the administration is also working to stop drug rebates to PBMs. The Pharmaceutical Care Management Association (PCMA), which represents pharmacy benefit managers, issued a report recently blaming high drug prices on drug makers, not PBMs. In the report, Mark Merritt, PCMA’s president and CEO, said the findings supported the belief that drug makers set and raise prices unrelated to the rebates they negotiate with PBMs.
    [Show full text]
  • Patient Access to Care and Treatments in the Cost-Shifting Era
    LEAD AUTHOR: Ralph D. McKibbin, MD, FACP, FACG, AGAF PATIENT ACCESS TO CARE AND TREATMENTS IN THE COST-SHIFTING ERA: Preserving the Patient-Provider Decision-Making Relationship A COLLABORATIVE PROJECT OF THE DIGESTIVE DISEASE NATIONAL COALITION TABLE OF CONTENTS 3 The Problem 4 Background 5 Common Medication and Medical Supply Utilization Programs and Cost-Shifting Tactics 5 Quantity Limits 5 Step Therapy 7 Medication Tiers 7 Non-Medical Switching for Drug Treatments 8 Non-Medical Switching for Medical Supplies 10 Prior Authorization 11 Cost Shifting and Co-Pay Accumulator Adjustment Programs 12 The Path to Improvement 13 The Basis for Change 13 Clinical Validity 13 Continuity of Care 14 Transparency and Fairness 14 Timely Access and Administrative Efficiency 14 Alternatives and Exemptions 15 Going Forward 15 The Coalition 15 Mission 15 Digestive Diseases 15 White Paper Review Panel 16 DDNC Constituent Members 16 DDNC Institutional Members 17 Literature Review Patient Access to Care and Treatments in the Cost-Shifting Era 2 The Problem The patient-provider relationship is the cornerstone of quality healthcare. A 2017 survey from the Council of Accountable Physician Practices (CAPP) found that consumers believe patient-provider relationships are the single most important factor in quality care.1 Through shared decision-making the patient and provider will develop a plan of care which meets their needs and expectations. Care guidelines are often used to establish safe and effective therapeutic plans. However, even peer reviewed guidelines acknowledge limitations and the need to individualize treatment decisions. Patients with rare, complex, and chronic diseases often need high-cost specialty medications to manage their conditions and maintain their health.
    [Show full text]